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Abstract 
With the rapidly expanding evidence on brain structural and functional changes in type 
2 diabetes mellitus (T2DM) patients, there is an increasing need to update our 
understanding on how T2DM associates with dementia as well as the underlying 
pathophysiological mechanisms. A literature search of T2DM and dementia or cognition 
impairments was carried out in electronic databases Medline, EMBASE, and Google 
Scholar. In this review, the chosen evidence was limited to human subject studies only, 
and data on either type 1 diabetes mellitus (T1DM) or non-classified diabetes were 
excluded. T2DM is a risk factor for both vascular dementia (VaD) and Alzheimer's 
disease (AD), although AD pathological marker studies have not provided sufficient 
evidence. T2DM interacts additively or synergistically with many factors including old 
age, hypertension, total cholesterol, and APOE ε4 carrier status for impaired cognition 
functions seen in patients with T2DM. In addition, comorbid T2DM can worsen the 
clinical presentations of patients with either AD or VaD. In summary, T2DM increases 
the risk for AD through different mechanisms for VaD although some mechanisms may 
overlap. Tau-related neurofibrillary tangles instead of β amyloid plaques are more likely 
to be the pathological biomarkers for T2DM-related dementia. Degeneration of neurons 
in the brain, impaired regional blood supply/metabolism, and genetic predisposition are 
all involved in T2DM-associated dementia or cognitive impairments.  
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T2DM and Dementia: introduction 
Type 2 diabetes mellitus (T2DM) is one of the most common chronic metabolic 
diseases, which affects more than 300 million people worldwide [1]. With its defining 
characteristic of impaired glucose regulation, T2DM progresses clinically with slowly 
declining functions in multiple body organs and systems. Impaired cognitive functions 
are often seen in patients with T2DM. Dementia is a condition with impaired functions 
in language, memory, and execution functions. Based on etiology and clinical features, 
people with dementia can be classified into Alzheimer’s disease (AD), vascular 
dementia (VaD), frontotemporal dementia, Lewy body dementia and non-specific 
dementia. In this review, T2DM will be examined for its associations with the two most 
common types of dementia: AD and VaD, which make more than 95% of all dementia 
cases. The underlying mechanisms of T2DM associated dementia will also be reviewed 
based on the expanding knowledge obtained from imaging and molecular pathological 
studies on brain structural and functional changes in patients with T2DM.  
 
T2DM as a Risk Factor for Dementia 
In 1996, a report from the Rotterdam study showed that T2DM was positively 
associated with dementia [2]. According to a 7-year follow-up study, patients with newly 
diagnosed T2DM had a 63% higher risk for developing dementia than those without 
T2DM [3]. From a retrospective study, hospital-admitted T2DM patients had a relative 
risk (RR) of 1.37 for dementia compared to controls [4]. By contrast, the RR for 
dementia diagnosis was 1.56 among newly onset T2DM patients compared to those 
participants without T2DM [5]. The increased risk for dementia in T2DM patients was 
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associated with many factors (Table 1), including age [6, 7], apolipoprotein E (APOE) 
ε4 carrier status [6], and medications, such as oral hypoglycemic agents and use of 
statins (lipid metabolism modifying agent) [6]. Other factors such as gender [7, 8], 
ethnicity [9], and body height [8] were also shown to be significantly associated with 
cognition changes in T2DM patients. Although APOE ε4 carrier status did not attain 
significance by itself [10, 11], these T2DM patients carrying one or two APOE ε4 allele 
had a significantly higher risk of dementia (both AD and VaD) than those who were 
negative for T2DM or APOE ε4 allele [12]. In addition, the dementia risk for patients 
with T2DM and stroke is eight times more possible to increase relative to that for those 
without T2DM or stroke [13].  
 
Pathological Mechanisms Underlying the Impaired Cognition Functions  
Impaired cognition functions in patients with T2DM were manifested in a variety of 
domains, such as attention [14, 15, 16], execution [14, 15, 16, 17, 18], information 
processing speed [9, 14, 16, 18, 19, 20], working memory [14, 15, 17, 18], and verbal 
memory [16, 20, 21, 22, 23]. Impaired cognition functions were associated with not only 
subcortical ischemic changes in the brain but also brain atrophy [14]. The atrophic brain 
changes associated with T2DM will be discussed in details in a separate section next. 
Worse execution function and memory are correlated predominantly with less gray 
matter density and reduced glucose metabolism in fronto-temporal areas [24]. The 
impaired execution function was also shown to be associated with the widespread 
white matter abnormalities [15]. T2DM patients performed significantly worse in 
language [25, 26] and visuospatial abilities [15, 19, 21, 25, 26] than those without 
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T2DM. In one study with a relatively small sample size, T2DM was found to be 
associated with a lower level of semantic memory in older adults than in those without 
T2DM, but not with episodic memory, working memory, visuospatial ability or global 
cognition [27]. Verbal memory impairment was associated with compromised 
microstructural integrity of the left parahippocampal gyrus [23]. 
The status of T2DM patients is usually described with its duration and overall glycemic 
control. Long duration of T2DM was associated with a poor cognitive function [28] 
especially on attention, working memory, and execution function [29]. For patients with 
T2DM, cognitive function was shown to be negatively associated with HbA1c [21]. The 
inverse relationship between HbA1c and cognitive performance was even seen in non-
diabetic subjects [30]. Therefore, hyperglycemia is associated with both impaired 
cognition functions and atrophic changes of the brain. High plasma glucose levels 
within the normal range (<6.1 mmol/L) were associated with atrophy in the 
hippocampus and amygdala [31]. On the other hand, T2DM patients with 
normoglycemia lost less whole-brain volume and exhibited a lower rate of converting 
mild cognitive impairment (MCI) to AD than those with hyperglycemia [32]. Both 
advanced glycation end products (AGEs) and glycoxidations were elevated in patients 
with T2DM compared to controls [33, 34, 35], which are important for the pathogenesis 
of T2DM and diabetic compliations. In addition, serum levels of AGEs, and C-reactive 
protein (CRP) were significantly increased in elderly patients with both MCI and T2DM 
compared to those with T2DM only [36]. In AD patients, AGEs were found to be 
elevated in the central nervous system [37] and were present mainly with intracellular 
neurofibrillary tangles (NFTs) [38]. The evidence suggested glycation, oxidative stress 
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as well as inflammation were involved in the impaired cognition functions in patients 
with T2DM (Table 2). Although insulin treatment was shown to increase the odds ratio 
of dementia in T2DM patients [2, 7, 39], it might simply indicate a more severe status of 
diabetes. 
T2DM patients with stable HbA1c levels over time had better cognition functions than 
those with fluctuating HbA1c levels [40]. Therefore, a fluctuating glucose level was 
suggested to be involved in the cognition decline in T2DM patients as impaired 
cognitions were seen among T2DM patients with hypoglycemic episodes as well [41, 
42] (Figure 1). For instance, the risk of dementia in T2DM patients was positively 
correlated with the number of hypoglycemic episodes [41]. The RR was 1.6 for 
dementia in T2DM patients who had hypoglycemic episodes compared to those who 
did not have hypoglycemia after controlling for age and gender [7]. Moreover, severe 
hypoglycemia was associated with poor cognition functions and an accelerated 
cognitive decline in T2DM patients [42].  
Other factors such as hypertension and vascular changes may also contribute to the 
cognition impairments seen in T2DM patients (Figure 1). Dementia was significantly 
and independently associated with hypertension in T2DM patients [43]. The cognitive 
impairment prevalence was found to be significantly higher in people with both T2DM 
and hypertension than in those normotensive T2DM patients [44]. Small vessel disease 
not only could predict future cognitive decline in elderly people with T2DM [45] but also 
was associated with the hippocampal atrophic changes [46] (Figure 1). Further, 
accelerated cognitive decline in patients with T2DM was associated with vascular 
damages [47]; arterial stiffness was increased and significantly associated with 
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cognition impairments in T2DM patients [16].  
T2DM was also shown as a risk factor for VaD [48, 49, 50] and it affected VaD more 
than AD [2] (Figure 1). The high overlap rate between dementia and ischemic stroke 
suggested that vascular events play an important role in the pathogenesis of T2DM-
associated dementia [3]. Lastly, patients with both T2DM and VaD showed a 
significantly earlier onset of VaD, a faster rate of cognitive decline, and a greater 
prevalence of neuropsychiatric symptoms than patients with VaD only [50]—these 
findings suggesting that T2DM had either additive or synergistic effects with VaD to 
worsen the clinical presentations.  
T2DM patients with severe diabetic retinal disease have a 42% increased risk of 
incident dementia [51]. On the contrary, one report showed that the severity of diabetic 
retinopathy was demonstrated to be inversely associated with the cognition 
impairments in T2DM patients [52]. In addition, the presence and number of 
microinfarcts or microbleeds were unrelated to cognitive performance in patients with 
T2DM [53]. Therefore, unlike other factors, the role of micorvascular changes is 
inconclusive for T2DM associated cognitive impairments.   
 
T2DM and Atrophic Brain Changes 
Atrophic brain changes in T2DM patients were manifested in volume changes either for 
the whole brain or for regional brain areas (Table 1). Whole brain atrophy was 
observed in many studies [19, 47, 54, 55, 56] except one [57] for patients with T2DM. 
The cerebral atrophy in T2DM patients was associated with an increased lateral 
ventricle volume [56, 58]. In addition, patients with AD and T2DM had more severe 
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cortical atrophy compared with the AD only group [59]. As sensitive early markers of 
AD-type neuropathology, hippocampal and amygdalar atrophy seen in T2DM were 
independent of vascular pathology [59, 60]. The atrophic hippocampus was reported in 
some studies [19, 22, 41, 54, 55], but T2DM-related brain volume reductions were 
reported to be restricted to the hippocampus in other studies [23, 61]. In one report, 
patients with T2DM had a greater whole brain atrophy but not hippocampal atrophy in 
comparison to controls [62]. T2DM was also reported to be associated with a lower 
bilateral frontal and parietal cortical thickness than in those without T2DM [63].  
The association between T2DM and gray matter (GM) or white matter (WM) was also 
reported by many studies. For example, T2DM was associated with a smaller GM 
volume [58]. T2DM patients showed extensively decreased GM volume compared to 
healthy controls in certain brain regions, including the superior and middle temporal 
gyrus, the superior and medial frontal gyrus and the middle occipital gyrus [64]. T2DM-
related GM loss was seen mainly in medial temporal, anterior cingulate, and medial 
frontal lobes, whereas WM loss was distributed in frontal and temporal regions [19].  
To summarize, T2DM was associated with atrophic brain changes, and variations in 
atrophic brain regions might reflect the interaction of many factors including T2DM 
duration, genetic predisposition, age, gender, and age at onset of T2DM [65]. 
 
T2DM and MCI 
MCI is generally considered to be a transitional phase between normal cognition and 
dementia. The MCI manifests as a stage of cognitive dysfunction with a mini mental 
status examination (MMSE) score falling between 23 and 27 out a toal of 30 points. On 
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average, the presence of T2DM at baseline shortened the duration of conversion from 
normal cognition to MCI by seven years [66]. Further, T2DM was associated with a 
higher MCI prevalence than in the general population [67, 68]. Patients with both T2DM 
and MCI had a faster cognitive deterioration process than patients with MCI only [32]; 
this finding suggested an interaction between T2DM and MCI. However, the 
association between T2DM and non-amnestic MCI was attenuated after socioeconomic 
and vascular risk factors were controlled [68].  
Age [69, 70], blood pressure [69], body mass index (BMI) [71], gender [72], current 
smoking status [27, 67, 71], duration of diabetes [67, 71, 73], fasting blood glucose 
(FBG) [67], HbA1c [67, 71], high-density lipoprotein cholesterol [71], immunoreactive 
insulin [67], total cholesterol [71], and triglycerides [71] were involved in developing 
MCI in T2DM patients. Age, education, and systolic blood pressure were significantly 
associated with an increased risk of MCI in older patients with T2DM [69]. High blood 
pressure [73] and older age [70] were risk factors for cognition impairments while 
education had a protective role against dementia [70]. Older age (>75 years) and long 
duration of diabetes are major risk factors for converting MCI to dementia, while the 
use of oral hypoglycemic agents or statins was associated with a significantly reduced 
risk for converting MCI to dementia [74]. T2DM has been found to be associated with 
MCI or MCI subtypes in middle-aged (50-65 years old) subjects but not in elderly 
individuals (66-80 years old) [72]. However, T2DM was shown to be associated with an 
increased risk of MCI in an elderly group of subjects (70 years and older) in another 
study [75]. High BMI, high 2-hour postprandial glucose, and poor glycemic control were 
significant independent predictors of cognition impairments in patients with both T2DM 
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and MCI [76]. T2DM patients with MCI had a longer duration of diabetes [77, 78, 79], 
fewer years of education [77], higher HbA1c [78, 79], higher low density lipoprotein 
(LDL) cholesterol [78], higher triglyceride [78] and higher fasting blood glucose (FBG) 
[77] than T2DM patients without cognitive impairment. Cognition functions were 
inversely correlated with T2DM duration [77], FBG [77], history of hypertension [77], 
non-high-density lipoprotein cholesterol [71], and total cholesterol [78]. Insulin 
treatment was associated with a lower level of cognitive performance level in T2DM 
patients with MCI than in patients with T2DM only [79], however, the insulin treatment 
might simply indicate a more severe status of diabetes, as stated earlier.  
T2DM may worsen the clinical presentation of patients with MCI by impairing 
psychomotor functions [80]. In addition, patients with both MCI and T2DM had a worse 
outcome in attention, information processing speed, and memory than non-diabetic 
MCI patients [81]. T2DM patients with MCI were shown to have a lower volume of the 
left middle temporal gyrus (MTG) than patients with T2DM only [64]. The atrophic 
changes in MTG were correlated positively with the cognitive performance score of 
Montreal Cognitive Assessment (MoCA) [64]. Therefore, structural changes can be 
observed in certain brain areas in the patients with T2DM who showed an early stage 
of cognitive impairment.  
 
T2DM as a Risk Factor for AD 
As the most common type of dementia, AD progresses clinically with impaired cognition 
functions, including memory. T2DM was shown to be associated with an increased risk 
of AD [82]. In 1999, the Rotterdam study reported that T2DM could double the risk of 
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AD [39]. More recently, T2DM was shown to be associated with a 60% increase of AD 
risk [83]. The association between T2DM and AD was not observed in one study with 
very old T2DM subjects (≥80 years old) (48). The association between T2DM and AD 
was probably specific with the age at onset of T2DM as the same relationship was 
observed between the age at onset of T2DM and MCI (72). Although the cortical 
atrophy in T2DM was reported to resemble the pattern as in preclinical AD [19], the 
presence of T2DM does not affect amyloid and neurofibrillary tangle burden in a 
sample of clinically and pathologically confirmed AD cases [84]. In addition, diffuse and 
neuritic plaques were not more common in T2DM than in control subjects [85]. The 11C 
Pittsburgh compound B (11C-PiB) (an amyloid plaque marker) retention ratio was 
similar in diabetic individuals versus non-diabetic individuals [86]. This finding 
suggested that the amyloid load was not significantly influenced by T2DM status. 
Moreover, the cognition impairments in T2DM were not associated with the AD-type 
pathology [87]. On the contrary, the T2DM was shown to be negatively associated with 
AD but positively associated with VaD [88]. For example, fewer neuritic plaques and 
NFTs in the cerebral cortex and hippocampus have been shown in diabetics than in the 
non-diabetics [89]. Hypometabolism in AD signature regions was two times more likely 
to be seen in diabetics than in nondiabetics [86]. It is likely that abnormalities in glucose 
metabolism interact with genetic predisposition leading to cognition decline in patients 
with T2DM (Figure 1). For instance, T2DM and APOE ε4 allele synergistically 
increased the number of pathological changes, such as neuritic plaques in 
hippocampus, NFTs in the cortex and hippocampus, and amyloid angiopathy in the 
brain [49]. Therefore, T2DM may accelerate the already existing cognitive impairments, 
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and the deteriorating effects of T2DM are more prominent in people with certain genetic 
predispositions (Figure 1). For example, individuals with both T2DM and APOE ε4 
allele had a risk ratio (RR) of 5.5 for AD compared with those with neither of them [49]. 
Lastly, a higher prevalence of T2DM or impaired glucose metabolism in patients with 
AD than in control subjects supported the involvement of impaired glucose metabolism 
in AD development [85]. On one hand, T2DM could worsen already impaired cognition 
functions through additive or synergistic effects with AD [90]. On the other hand, insulin 
therapy was shown to be effective in slowing cognitive decline in patients with both AD 
and T2DM [91]. 
Other factors are associated with an increased AD risk in T2DM patients. For instance, 
the use of statins might decrease the risk of AD in patients with T2DM while no benefit 
was observed in non-AD type dementia [92]. A low insulin response at baseline was 
associated with a higher cumulative risk of AD, and the association was stronger in 
subjects without the APOE ε4 allele [93]. Insulin resistance might be a signal of AD risk, 
which was associated with reduced cerebral glucose metabolism and subtle cognitive 
impairments at the early stage of T2DM, even before the onset of MCI [94]. Increasing 
insulin resistance was associated with more amygdalar atrophy in T2DM patients [60]. 
Patients with insulin resistance had increased the levels of Aβ and inflammatory agents 
in brain [95]. All these pathological changes could be responsible for the impaired 
cognition functions seen in T2DM patients (Figure 1 and Table 2).  
At molecular and cellular level, the deficiency of insulin-PI3K-AKT signaling was more 
severe in individuals with both T2DM and AD than in those with either one alone [96]. 
The level of PI3K-AKT signaling was negatively correlated with tau phosphorylation 
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[96]. In addition, both neuronal membrane glucose transporter 3 and GlcNAcylation 
levels of tau were decreased in the brain of T2DM patients due to an increased tau 
phosphorylation [97]. In T2DM patients, an increased level of phosphorylated tau might 
cause neurons to degenerate by causing NFTs to accumulate in these cells.  
T2DM and AD Biomarker Levels 
Amyloid-β (Aβ) plaques and NFTs are pathological biomarkers for AD, while T2DM is 
characterized by the deposition of islet amyloid polypeptide (IAPP, also known as 
amylin) within beta cells of the pancreatic islets. All these biomarkers (Aβ plaques, 
NFTs and amylin) are in the form of mis-folded proteins. Aβ autoantibody levels 
increased 45% in patients with T2DM compared with age-matched controls [98]. 
However, T2DM was associated neither with 11C- Pittsburgh compound B standardized 
uptake value ratio in any brain region for measuring Aβ plaques nor with cerebrospinal 
fluid (CSF) Aβ42 levels [63]. By contrast, T2DM was associated significantly with 
increased levels of CSF total tau and phosphorylated tau (pTau) [63]. Tau is a 
microtubule-associated protein, and the pTau level is closely related to the formation of 
NFTs. T2DM patients have a higher pTau level measured from frontal cortices than the 
control subjects [97]. So Tau and pTau instead of β amyloid plaques is more likely to 
be the sensitive pathological biomarker for T2DM- related dementia. However, studying 
biomarker changes longitudinally and/or pathological changes from autopsies is 
needed for disclosing relationship between T2DM and dementia. 
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Factors Influence MCI or Dementia 
Risk 
Abnormalities in Brain 
Structure and Metabolism 
Impaired Cognition 
Functions in T2DM 
Patients 
Age (6, 7, 69, 70, 72); 
Age at Onset of T2DM (65); 
APOE ε4 (6, 12, 49, 93); 
Blood Pressure (43, 44, 69, 73, 
77); 
Blood Lipids (71, 78) 
Body Mass Index (8, 71, 76);  
Current Smoking Status (27, 67, 
71) 
Duration of T2DM (28, 29, 67, 71, 
73, 77, 78, 79); 
Ethnicity (9); 
Education (69, 77); 
Fluctuating Glucose Level and  
Glycemic Control (7, 21, 31, 32, 
40, 41, 42, 67, 71, 76, 77, 78, 79);  
Gender (7, 8, 72);  
Medications (6, 74, 92); 
Stroke (13);  
 
Amygdala Atrophy (31, 59, 
60);  
Brain Atrophy (14,19, 47, 
54, 55, 56, 58, 62);   
Cortical Atrophy (19, 59, 
63); 
GM abnormality (19, 24, 58, 
59, 63, 64); 
Hippocampus Atrophy (19, 
22, 23, 31, 41, 46, 54, 55, 
59, 60, 61); 
Increased Lateral Ventricle 
Volume (56, 58); 
Left parahippocampal 
Gyrus (23); 
Reduced glucose 
metabolism (14, 24); 
WM abnormality (15, 19); 
 
Attention (14, 15, 
16, 29, 81); 
Execution (14, 15, 
16, 17, 18, 29); 
Information 
Processing Speed 
(9, 14, 16, 18, 19, 
20); 
Language (25, 26); 
Psychomotor 
functions (80); 
Verbal Memory 
(16, 20, 21, 22, 
23); 
Visuospatial 
Abilities (15, 19, 
21, 25, 26) 
Working Memory 
(14, 15, 17, 18, 27, 
29, 81); 
 
Table 1. Factors interact with T2DM to affect brain structure and functions of 
metabolism and cognition. APOE ε4: apolipoprotein E ε4; T2DM: type 2 diabetes 
mellitus; GM: gray matter; WM: white matter 
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Pathological 
Mechanisms for T2DM 
Related Dementia 
T2DM Related 
VaD 
Pathogenesis 
T2DM related AD 
Pathogenesis 
Glycation (33, 36, 37, 
38);  
Glycoxidation (34); 
Inflammation (36, 95) 
Vascular changes (16, 
45, 46, 47 
 
Cerebrovascular 
Events (3, 13); 
Impaired glucose 
metabolism (85, 86, 94); 
Insulin Resistance (60, 93, 
94, 95); 
Increased Tau 
phosphorylation (63, 96, 97) 
 
Table 2. Pathological mechanisms for T2DM related Dementia, AD and VaD. MCI: mild 
cognitive impairment; T2DM: type 2 diabetes mellitus; AD: Alzheimer’s disease; APOE 
ε4: apolipoprotein E ε4; VaD: Vascular dementia  
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Figure 1. The possible pathological mechanisms for T2DM related dementia. AD: 
Alzheimer’s disease; APOE: apolipoprotein E; VaD: Vascular dementia.  
	
